Faster access to new and more effective medicines
A long-term collaboration between AstraZeneca and Chalmers led to the founding of InSingulo in 2017. The core business is set up around the challenges of biophysics in drug discovery using single-molecule microscopy.
The method developed by InSingulo provides improved sensitivity and low reagent consumption which is extremely valuable for new and challenging drug targets. This is especially tr